Fig. 2
From: Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain
Treatments prescribed to migraine patients from May 2020 to April 2022, per class of treatment, as a percentage of total migraine patients treated from May 2020 to April 2022 (Cohort A). CGRP, Calcitonin gene-related peptide; NSAIDs, Non-steroidal anti-inflammatory drugs. Note The percentages add up to more than 100% as patients may have been prescribed more than one class of treatment over the analyzed period